Moth tops most-recalled drug TV ads

Share this article:
Two ads for Lunesta's Sepracor ranked as the most-recalled new prescription drug spots of 2006, followed by two spots for Novartis' Zelnorm, according to a survey by IAG Research.

In the most-recalled spot, created by McCann-Erickson HumanCare, the ubiquitous luna moth lands in a man's room as a voice-over intones: “Are you at home trying to sleep, but your mind is still at the office?” In the second most-recalled spot, the moth flies through nocturnal vistas before landing on a woman's shoulder while questions flash on the screen: “Why's my mind so restless? Can anything help?”

Two executions from the Zelnorm “Tummies” series, by Deutsch, placed as the third- and fourth-most recalled ads. Ads featuring the Nasonex Bee, by BBDO New York, placed fifth and tenth. Rounding out the top ten were spots for GSK's Boniva; Merck/Schering-Plough's Vytorin; Merck's Fosamax; and GSK's Valtrex.

Fariba Zamaniyan, VP at IAG's pharmaceutical practice, said: “The above average performances achieved by these brands confirm that direct-to-consumer advertising for prescription drugs can achieve breakthrough and brand recognition, even within the rigid guidelines this category faces.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...